All Content

Diagnosing and Treating MELAS: Issues for Clinicians

Jan 8, 2018

Differential diagnosis and treatment of mitochondrial encephalomyopathy lactic acidosis and stroke-like syndrome.

Statins and Risk of Parkinson Disease

Veronica Hackethal, MD

Dec 26, 2017

There has been long-running controversy regarding the association between statins and PD risk. Two studies with conflicting results are examined here.

Cognitive Enhancers Generally Make No Clinically Important Difference in AD

Veronica Hackethal, MD

Dec 26, 2017

Findings from a new meta-analysis suggest these medications may be most effective in improving cognition in Alzheimer disease.

New Insights on Stroke: Atypical Antipsychotics and Other Considerations

Mark L. Fuerst

Dec 21, 2017

Clinical implications of three new studies on treatments that may increase risk of—or mitigate harm from—stroke in older patients.

CMEs for Neurologists in 2018

Veronica Hackethal, MD

Dec 20, 2017

Featured CMEs for neurology, neuro-ophthalmology, neuroradiology, and neurosurgery, as well as a range of other topics.

New Hope in the Fight Against Alzheimer Disease

Heidi Moawad, MD

Dec 18, 2017

Bill Gates has taken on an ambitious new project—fighting Alzheimer disease.

New Neurosurgery Tech of Interest to Neurologists

Veronica Hackethal, MD

Dec 14, 2017

A summary of cutting-edge technology, including the world’s smallest fully implantable spinal cord neurostimulator for the treatment of chronic pain.

Low-Dose Aspirin and the Risk of Intracranial Bleeds

Bobby Lazzara, MD

Dec 14, 2017

Low dose aspirin use is becoming almost ubiquitous in cardiovascular risk modification, cancer risk modification, and in other areas whether appropriately indicated…or not.

Patient Empowerment and Self-Management Neurotechnology to Watch in 2018

Veronica Hackethal, MD

Dec 14, 2017

Tools to help users monitor and detect tinnitus, control post-stroke symptoms, improve seizure monitoring, and more.

A Clinical Update of Intracerebral Hemorrhage

Dec 13, 2017

A summary of current treatment guidelines, application, and emerging developments in the area of spontaneous nontraumatic ICH.

Exenatide: A Potential Disease-Modifying Agent in PD?

Veronica Hackethal, MD

Dec 12, 2017

A new study found that the diabetes drug exenatide is associated with improved and sustained off-medication motor symptoms in PD, representing a major new avenue for treating the disorder.

A Case of Cerebral Amyloid Angiopathy-Related Inflammation With Pathologic Features

Dec 11, 2017

A 71-year-old woman presented to the emergency department with subacute headaches and altered behavior that was initially attributed to emotional distress. What did the tests show?